CD276 and neoplasm: B7-H3 has attracted considerable interest as promising target for cancer immunotherapy because it is not only overexpressed on tumor cells in various types of cancer including GI cancer (9, 39, 40), but also on tumor-associated endothelial and stromal cells (41, 42).